Assessment of lymph node metastases in patients with ovarian high-grade serous carcinoma: Incremental diagnostic value of dual-energy CT combined with morphologic parameters
- 9 April 2025
- journal article
- Published by Elsevier in European Journal of Radiology
- Vol. 187, 112107
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Clinical value of dual-energy CT for predicting occult metastasis in central neck lymph nodes of papillary thyroid carcinomaEuropean Radiology, 2023
- Predicting axillary lymph node metastasis in breast cancer using the similarity of quantitative dual-energy CT parameters between the primary lesion and axillary lymph nodeJapanese Journal of Radiology, 2022
- What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?Gynecologic Oncology, 2021
- Cancer of the ovary, fallopian tube, and peritoneumInternational Journal of Gynecology & Obstetrics, 2018
- Metastatic and non-metastatic lymph nodes: quantification and different distribution of iodine uptake assessed by dual-energy CTEuropean Radiology, 2017
- An update on the role of PET/CT and PET/MRI in ovarian cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Iodine quantification to characterize primary lesions, metastatic and non-metastatic lymph nodes in lung cancers by dual energy computed tomography: An initial experienceEuropean Journal of Radiology, 2016
- Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CTEuropean Radiology, 2013
- Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysisEuropean Journal of Radiology, 2012
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009